empty
 
 
en
Search
Support
Instant account opening
Trading Platform
Deposit/Withdraw
Search
P2P Exchange Financial Markets For Partners Forum About InstaSpot
en
For Traders
Charts
#DVAX

#DVAX (Dynavax Technologies Corporation). Exchange rate and online charts.

#DHR Return to the list of instruments #DXCM

Currency converter

Dynavax Technologies Corporation
15.49 USD
23 Jan 2026 22:59
Price Change (% chg)
$-0.04
(-0.26%)
Prev Close
Prev Close

Closing price, the previous day.
$15.63
Open
Open

Opening price.
$15.67
Day's High
Day's High

The highest price over the last trading day.
$15.64
Day's Low
Day's Low

The lowest price over the last trading day
$15.49
Week High
Week High

Price range high in the last week
$15.66
Week Low
Week Low

Price range low in the last week
$15.49
Download archive
Buy
15.49
Sell
15.49
Open the chart in full screen view
Buy
15.49
Sell
15.49
Download archive
Open the chart in full screen view

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

Can't speak right now?
Ask your question in the chat.